The global fluoroquinolones and fluoroquinolones with the most effective antimicrobial agents for clinical use, are now the best available treatment options for patients with acute respiratory tract infections. Fluoroquinolones are a broad-spectrum class of antibacterial agents with high safety profiles. Currently, the only FDA-approved oral fluoroquinolones are the tetracyclines (TCs), which have a narrow therapeutic index. Fluoroquinolones are currently the only FDA-approved oral therapy for acute sinusitis caused by the gram-negative bacteria, Escherichia coli, and Pseudomonas aeruginosa, but they have a relatively high risk of serious infections, such as pneumonia, bronchitis, and sinusitis, due to the high risk of serious adverse events associated with fluoroquinolone use.
This study aimed to evaluate the efficacy and safety of fluoroquinolones for acute sinusitis caused by Pseudomonas aeruginosa.
Fluoroquinolones were most effective against P. aeruginosa, with a low risk of serious adverse events. Patients were treated with 100 mg/dose of each fluoroquinolone for up to 14 days. The rates of serious adverse events, including death, hospitalization, and requirement for intensive care, were higher with fluoroquinolones (16/10, 24/12, and 17/12, respectively).
The study has some limitations. The study used a single-centre, randomized, double-blind, placebo-controlled study design with a single-arm design to establish the efficacy of fluoroquinolones for acute sinusitis in patients who had not been treated with a single fluoroquinolone for a period of at least 1 month. Moreover, the results of this study are limited by the short duration of the study and the inclusion of patients who received a single dose of fluoroquinolone for a period of at least 2 months without the use of a fluoroquinolone for a period of more than 3 months.
Fluoroquinolones were effective against P. aeruginosa, which is a Gram-negative intracellular bacteria, was more than double than that of the fluoroquinolones. Patients who were treated with fluoroquinolones had a lower risk of serious adverse events.
Citation:Moule A, Gagnon G, et al. (2020) Fluoroquinolones for the treatment of acute sinusitis. PLoS ONE 11(11): e1006801. https://doi.org/10.1371/journal.pone.001006801
Editor:Dalaiya M. S. Patel, University of Alabama at Birmingham, UNITED STATES
Received:August 7, 2023;Accepted:March 13, 2020;Published:April 2, 2020
Copyright:© 2020 Moule et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability:The authors confirm that all data underlying the findings are fully available without restriction. The author(s) provided all the necessary information including the names of authors, publication year, year of publication, country of origin, sample size, drug type, and patient population. All relevant data are within the paper and its Supporting Information files.
Funding:The author(s) received no specific funding for this work.
Competing interests:The authors have declared that no competing interests exist.
The fluoroquinolones, particularly ciprofloxacin, have been the gold standard for the treatment of infections in clinical settings. The fluoroquinolones can be given to patients with uncomplicated or uncomplicated bacterial vaginosis and the fluoroquinolones are often prescribed to treat the same pathogens. However, the fluoroquinolones have a narrow therapeutic index, which means they can cause serious adverse events, which can be fatal. In the last decade, fluoroquinolones have been prescribed to treat most Gram-negative organisms and have a low risk of serious adverse events.
Background:Ciprofloxacin (CIP) is a commonly prescribed antibiotic and has significant implications in the treatment of many bacterial infections including Gram-positive and Gram-negative organisms. A key advantage of CIP is its broad-spectrum antimicrobial spectrum. However, the use of CIP in human patients poses risks and complications. Our study investigated the spectrum of CIP resistance to CIP by using the spectrophotometer, which is sensitive to the spectrinone-based assay.
This retrospective study was conducted to assess the efficacy of CIP in the treatment of respiratory tract infections in patients with bacterial sinusitis. We conducted a cross-sectional study to investigate the efficacy of CIP in the treatment of sinusitis.
We obtained information from the patients admitted to our hospital who received CIP for respiratory tract infections (RTIs) in our clinic from July 2013 to June 2015. Patients were divided into the control group (n=20) and the treated group (n=20). The patients in the control group received CIP (500 mg) on a daily basis. They were diagnosed with a bacterial sinusitis and were given antibiotics for a minimum of three days (day 1 and day 2). CIP was administered for three days in the treated group. The results of the antibiotic susceptibility were determined by the Clinical and Laboratory Standards Institute (CLSI) according to CLSI guidelines.
The antibiotic resistance in the two groups was comparable. Ciprofloxacin was highly effective in the treatment of RTIs (p<0.001). However, the duration of CIP therapy was significantly shorter than that of the control group (p=0.003). The incidence of resistance was similar in both treatment groups, except for the duration of CIP treatment (p=0.05). The antibiotic resistance profile did not show any significant difference between the groups. The most common resistance pattern was Ciprofloxacin-resistance (30/20), followed by Ciprofloxacin-resistance (9/20), Ciprofloxacin-resistance (5/20), Ciprofloxacin-resistance (3/20) and Ciprofloxacin-resistance (2/20).
The use of CIP in patients with bacterial sinusitis poses a significant concern. This study demonstrated that the CIP was a potent drug in the treatment of sinusitis in patients with bacterial sinusitis. The use of CIP in patients with respiratory tract infections poses a significant risk. This study was designed to determine the clinical efficacy of CIP in sinusitis patients.
Dr. Paul E. Smith is the founder and managing director of the Global Bacterial Skin Outgrowth Treatment Program. His research interests include antibiotic resistance, antimicrobial therapy, and personalized medicine. Smith is a research consultant for Boehringer Ingelheim Pharmaceuticals and Pfizer Inc. and a member of the National Institute of Allergy and Infectious Diseases, American Academy of Pediatrics and the Centers for Disease Control and Prevention (CDC). E. Smith has received research funding from Pfizer Inc. from the National Institutes of Health, the Infectious Diseases Research Council of the National Institutes of Health, the American Medical Association, and the National Institute of Allergy and Infectious Diseases. He is the recipient of grants from the National Heart, Lung and Blood Institute, the National Institute of Dental and Blood Products, the National Institute on Drug Abuse, the American Medical Association, and the National Institutes of Health.
*Corresponding author:
Smith, MD, Vice President, Center for Skin, Skin and Bone Infection, Department of Dermatology, Department of Pediatrics, George M. Covington School of Medicine, The University of Miami, 31005 Miami, FL 32315-7236, USA.
Received:May 16, 2017;Accepted:December 6, 2017;Published:December 29, 2017.
Copyright:© 2017 These authors. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Atremendous achievement of high-quality guidelines for the management of acute urinary tract infections (AUTIs) has been a cornerstone of therapy for years and remains a significant burden on the global health care system. As one of the most common AUTIs, urinary tract infections are a common cause of morbidity and mortality, particularly among immunocompromised patients. While effective, both otolaryngologists and healthcare professionals are concerned about the long-term implications of these infections and the necessity for additional monitoring.
Otolaryngologists have long recommended the use of antibiotics for acute otitis media, as well as for treatment of infections secondary to bacterial sinusitis. The choice of antibiotic is influenced by individual factors such as the severity of the infection and the patient’s overall health status. It is critical for patients to understand the potential side effects and to seek medical advice promptly if they develop any symptoms of infection.
Atypical therapies for otitis media are based on the belief that antibiotics, such as the fluoroquinolones ciprofloxacin and levofloxacin, are effective in treating infections that can be caused by bacteria, such asMycobacterium aviumcomplex (MAC) andNeisseria meningitidis. However, in some patients, antibiotic therapy may be ineffective and/or the infection is refractory to conventional treatment. Otolaryngologists are often hesitant to prescribe antibiotics because of concerns about the antibiotic’s potential side effects, and they are concerned about the cost and accessibility of antibiotics.
The primary choice of antibiotic is either a combination of levofloxacin and tetracycline, or a combination of levofloxacin and ciprofloxacin. Although effective, it is important to note that these therapies are associated with some side effects and the need for further investigation in patients with acute otitis media. The choice of antibiotic should be based on the patient’s overall health status, the severity of the infection, and the patient’s overall susceptibility profile. Furthermore, the choice of treatment should be individualized, considering factors such as the patient’s age, the presence of comorbidities, and the severity of the infection. In general, patients should be advised to have a screening for infections at baseline, including a urine culture to exclude MAC and otitis externa.
While otitis media can be successfully treated with these antibiotics, it is important for the physician to assess the patient’s overall susceptibility to the antibiotic and to conduct a urine culture to confirm the presence of MAC or otitis externa. In the past, otolaryngologists had been able to prescribe antibiotic therapy to treat acute otitis media by prescribing ciprofloxacin and levofloxacin for a broad spectrum of infections, while otolaryngologists now use ciprofloxacin and levofloxacin for a broader spectrum of infections.
Otolaryngologists have frequently advised against the use of antibiotics for acute otitis media because of the risk of ototoxicity. However, the risk of ototoxicity is higher in patients with compromised renal function, particularly those with a compromised renal function, which may lead to an increase in the risk of ototoxicity. Furthermore, some patients may be more susceptible to ototoxicity by the use of antibiotics that are not effective.
The most effective antibiotics available for the treatment of acute otitis media are tetracycline and doxycycline. Both are used to treat patients with acute otitis media who have no alternative treatments. Both drugs may be effective for patients with compromised renal function and are not recommended for use alone.
Gastrointestinal infections are caused by bacteria, such asEscherichia coli,Salmonellaspp., andYersinia pestisThey are frequently associated with the development of otitis media, and these infections are usually treatable by antibiotics.
Consumer ReportsRx. No. 2: Ciprofloxacin 500 mg
A generic form of Cipro, Cipro XR, and Cipro XR XR has been approved for use in adults and pediatric patients.
5: Cipro XR 500 mg
The brand Cipro XR is indicated for the treatment of acute otitis media (absence of signs and symptoms) in patients aged 5 years and older.
The brand Ciprofloxacin 500 mg is indicated for the treatment of infections caused by susceptible gram-positive and gram-negative organisms, including otitis media.
The brand Ciprofloxacin 500 mg is indicated for the treatment of infections caused by susceptible gram-positive and gram-negative organisms, including:
The brand Ciprofloxacin 500 mg is indicated for the treatment of infections caused by susceptible gram-negative organisms, including:
1.Ciprofloxacinis a fluoroquinolone antimicrobial agent. It is effective against most gram-positive and gram-negative organisms, including:
2.is a fluoroquinolone antibacterial agent.
3.
4.
Stade de France Pharmacy